Home / Market News / $REGN
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $1,075 From $917

Nov 17, 2026, 11:35 AM UTC · Primary ticker $REGN

Barclays has increased its price target for Regeneron Pharmaceuticals from $917 to $1,075. This indicates a more optimistic outlook from the firm regarding Regeneron's future performance and valuation, potentially signaling positive sentiment for investors.

Barclays has raised its price target for Regeneron Pharmaceuticals (REGN) from $917 to $1,075. This adjustment reflects Barclays' updated valuation assessment of the biotechnology company, likely driven by ongoing market analysis of its performance and prospects. For traders, this is a moderately positive signal, as a higher price target from a major investment bank can influence investor sentiment and potentially lead to short-term upward price momentum for REGN. While not a direct operational change, it suggests that analysts see increased value in the company, which could attract new investment or reinforce existing positions. The long-term implications depend on whether Regeneron's actual performance aligns with this revised valuation, but in the short term, it provides a bullish indicator.

$REGN positive Price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.